Dr. Reddys launches inhaler products for asthma
Hyderabad, September: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) has entered the inhaler segment in India with the launch of ‘Combihale’ – a combination of a steroid and a long acting bronchodilator. It is used in the treatment of asthma and is available in two combinations, Combihale FF (Formoterol + Fluticasone) and Combihale FB (Formoterol + Budesonide).
Combihale would be available along with ‘Redihaler*’, a dry powder inhalation device that was designed in-house and which will initially be given free of cost with Combihale.
Combihale comes in both Dry Powder Inhaler and Metered Dose Inhaler forms and is available in the following pack sizes:
Metered dose inhaler of 120 doses
Dry Powder capsules, 2 X 15’s blister caps along with the Redihaler device
Notes to the editor:
Inhaler market is currently valued at Rs 473 crores growing at over 17% annually (Source: ORG IMS)
Brief mode of action of Combihale:
Combihale is a combination of a steroid and a long acting bronchodilator
Combihale range of inhalational drugs are dispensed either through dry powder (DPI) or metered dose inhaler (MDI) forms
Upon oral inhalation, they selectively deposit the drug at the site where their action is needed.
These contain bronchodilator, which relax the constricted airways and corticosteroid, which limit inflammation and irritation in the airways in patients suffering from obstructive lung disease including Asthma
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
No comments yet.
Leave a comment